Compare WVE & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | ALVO |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Singapore | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2015 | 2021 |
| Metric | WVE | ALVO |
|---|---|---|
| Price | $5.35 | $4.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $29.81 | $8.00 |
| AVG Volume (30 Days) | ★ 3.1M | 864.3K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | $85.67 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.01 | $2.94 |
| 52 Week High | $21.73 | $9.25 |
| Indicator | WVE | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 67.98 |
| Support Level | $5.02 | $4.36 |
| Resistance Level | $6.39 | $4.59 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 23.93 | 76.76 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.